Pfizer Debt to Equity Ratio 2012-2025 | PFE
Current and historical debt to equity ratio values for Pfizer (PFE) over the last 10 years. The debt/equity ratio can be defined as a measure of a company's financial leverage calculated by dividing its long-term debt by stockholders' equity. Pfizer debt/equity for the three months ending December 31, 2025 was 0.62.
| Pfizer Debt/Equity Ratio Historical Data | |||
|---|---|---|---|
| Date | Long Term Debt | Shareholder's Equity | Debt to Equity Ratio |
| 2025-12-31 | $0.00B | 0.00 | |
| 2025-09-30 | $115.64B | $93.10B | 1.24 |
| 2025-06-30 | $117.08B | $89.01B | 1.32 |
| 2025-03-31 | $117.39B | $90.64B | 1.30 |
| 2024-12-31 | $124.90B | $88.50B | 1.41 |
| 2024-09-30 | $126.92B | $92.56B | 1.37 |
| 2024-06-30 | $128.22B | $87.98B | 1.46 |
| 2024-03-31 | $128.54B | $92.56B | 1.39 |
| 2023-12-31 | $137.21B | $89.29B | 1.54 |
| 2023-09-30 | $117.82B | $97.20B | 1.21 |
| 2023-06-30 | $120.88B | $99.29B | 1.22 |
| 2023-03-31 | $94.38B | $101.24B | 0.93 |
| 2022-12-31 | $101.29B | $95.92B | 1.06 |
| 2022-09-30 | $102.46B | $92.89B | 1.10 |
| 2022-06-30 | $107.82B | $87.47B | 1.23 |
| 2022-03-31 | $101.16B | $82.69B | 1.22 |
| 2021-12-31 | $104.01B | $77.46B | 1.34 |
| 2021-09-30 | $103.22B | $75.97B | 1.36 |
| 2021-06-30 | $99.61B | $70.32B | 1.42 |
| 2021-03-31 | $89.95B | $68.87B | 1.31 |
| 2020-12-31 | $90.76B | $63.47B | 1.43 |
| 2020-09-30 | $113.49B | $65.50B | 1.73 |
| 2020-06-30 | $113.37B | $64.56B | 1.76 |
| 2020-03-31 | $101.00B | $65.34B | 1.55 |
| 2019-12-31 | $104.15B | $63.45B | 1.64 |
| 2019-09-30 | $105.05B | $65.40B | 1.61 |
| 2019-06-30 | $96.27B | $59.92B | 1.61 |
| 2019-03-31 | $96.26B | $59.16B | 1.63 |
| 2018-12-31 | $95.66B | $63.76B | 1.50 |
| 2018-09-30 | $96.17B | $71.66B | 1.34 |
| 2018-06-30 | $94.86B | $70.12B | 1.35 |
| 2018-03-31 | $94.07B | $70.54B | 1.33 |
| 2017-12-31 | $100.14B | $71.66B | 1.40 |
| 2017-09-30 | $111.04B | $61.11B | 1.82 |
| 2017-06-30 | $109.86B | $58.69B | 1.87 |
| 2017-03-31 | $110.04B | $58.75B | 1.87 |
| 2016-12-31 | $111.78B | $59.84B | 1.87 |
| 2016-09-30 | $114.83B | $63.60B | 1.81 |
| 2016-06-30 | $107.59B | $63.07B | 1.71 |
| 2016-03-31 | $99.58B | $63.35B | 1.57 |
| 2015-12-31 | $102.38B | $65.00B | 1.58 |
| 2015-09-30 | $103.74B | $67.12B | 1.55 |
| 2015-06-30 | $93.70B | $67.18B | 1.40 |
| 2015-03-31 | $93.05B | $67.59B | 1.38 |
| 2014-12-31 | $95.94B | $71.62B | 1.34 |
| 2014-09-30 | $93.06B | $78.31B | 1.19 |
| 2014-06-30 | $95.66B | $76.96B | 1.24 |
| 2014-03-31 | $93.74B | $78.07B | 1.20 |
| 2013-12-31 | $95.48B | $76.62B | 1.25 |
| 2013-09-30 | $97.17B | $78.35B | 1.24 |
| 2013-06-30 | $100.36B | $78.98B | 1.27 |
| 2013-03-31 | $104.57B | $82.83B | 1.26 |
| 2012-12-31 | $104.12B | $81.68B | 1.28 |
| 2012-09-30 | $100.49B | $82.12B | 1.22 |
| 2012-06-30 | $102.88B | $79.96B | 1.29 |
| 2012-03-31 | $102.01B | $83.68B | 1.22 |
| 2011-12-31 | $105.38B | $82.62B | 1.28 |
| 2011-09-30 | $105.60B | $90.53B | 1.17 |
| 2011-06-30 | $106.94B | $88.96B | 1.20 |
| 2011-03-31 | $104.42B | $90.53B | 1.15 |
| 2010-12-31 | $106.75B | $88.27B | 1.21 |
| 2010-09-30 | $103.35B | $88.07B | 1.17 |
| 2010-06-30 | $104.19B | $86.88B | 1.20 |
| 2010-03-31 | $105.03B | $90.08B | 1.17 |
| 2009-12-31 | $122.50B | $90.45B | 1.35 |
| 2009-09-30 | $75.04B | $66.25B | 1.13 |
| 2009-06-30 | $76.10B | $63.24B | 1.20 |
| 2009-03-31 | $62.49B | $60.44B | 1.03 |
| 2008-12-31 | $53.41B | $57.74B | 0.93 |
| 2008-09-30 | $47.91B | $67.34B | 0.71 |
| 2008-06-30 | $49.95B | $66.57B | 0.75 |
| 2008-03-31 | $51.13B | $67.42B | 0.76 |
| 2007-12-31 | $50.26B | $65.01B | 0.77 |
| 2007-09-30 | $42.42B | $66.61B | 0.64 |
| 2007-06-30 | $42.31B | $68.09B | 0.62 |
| 2007-03-31 | $38.00B | $72.49B | 0.52 |
| 2006-12-31 | $44.19B | $71.36B | 0.62 |
| 2006-09-30 | $38.87B | $69.71B | 0.56 |
| 2006-06-30 | $43.06B | $68.49B | 0.63 |
| 2006-03-31 | $43.35B | $69.61B | 0.62 |
| 2005-12-31 | $51.21B | $65.76B | 0.78 |
| 2005-09-30 | $43.54B | $66.81B | 0.65 |
| 2005-06-30 | $47.00B | $65.33B | 0.72 |
| 2005-03-31 | $55.40B | $67.53B | 0.82 |
| 2004-12-31 | $54.80B | $68.28B | 0.80 |
| 2004-09-30 | $53.85B | $68.38B | 0.79 |
| 2004-06-30 | $53.26B | $66.71B | 0.80 |
| 2004-03-31 | $53.24B | $69.05B | 0.77 |
| 2003-12-31 | $51.40B | $65.38B | 0.79 |
| 2003-09-30 | $51.53B | $68.53B | 0.75 |
| 2003-06-30 | $53.98B | $70.28B | 0.77 |
| 2003-03-31 | $28.09B | $24.84B | 1.13 |
| 2002-12-31 | $26.41B | $19.95B | 1.32 |
| 2002-09-30 | $25.92B | $18.95B | 1.37 |
| 2002-06-30 | $23.74B | $18.83B | 1.26 |
| 2002-03-31 | $21.64B | $19.67B | 1.10 |
| 2001-12-31 | $20.86B | $18.29B | 1.14 |
| 2001-09-30 | $19.91B | $18.90B | 1.05 |
| 2001-06-30 | $19.13B | $17.82B | 1.07 |
| 2001-03-31 | $17.40B | $17.75B | 0.98 |
| 2000-12-31 | $17.43B | $16.08B | 1.08 |
| 2000-09-30 | $17.32B | $16.17B | 1.07 |
| 2000-06-30 | $17.07B | $14.97B | 1.14 |
| 2000-03-31 | $10.04B | $10.19B | 0.99 |
| 1999-12-31 | $11.69B | $8.89B | 1.32 |
| 1999-09-30 | $11.45B | $8.79B | 1.30 |
| 1999-06-30 | $10.99B | $8.65B | 1.27 |
| 1999-03-31 | $9.98B | $9.05B | 1.10 |
| 1998-12-31 | $9.49B | $8.81B | 1.08 |
| 1998-09-30 | $9.53B | $8.65B | 1.10 |
| 1998-06-30 | $8.20B | $8.31B | 0.99 |
| 1998-03-31 | $7.77B | $8.19B | 0.95 |
| 1997-12-31 | $7.40B | $7.93B | 0.93 |
| 1997-09-30 | $7.94B | $7.41B | 1.07 |
| 1997-06-30 | $8.56B | $7.17B | 1.19 |
| 1997-03-31 | $7.90B | $7.15B | 1.11 |
| 1996-12-31 | $7.71B | $6.95B | 1.11 |
| 1996-09-30 | $8.05B | $6.57B | 1.23 |
| 1996-06-30 | $7.64B | $5.98B | 1.28 |
| 1996-03-31 | $7.29B | $5.89B | 1.24 |
| 1995-12-31 | $7.22B | $5.51B | 1.31 |
| 1995-09-30 | $7.54B | $5.28B | 1.43 |
| 1995-06-30 | $8.12B | $4.83B | 1.68 |
| 1995-03-31 | $7.82B | $4.70B | 1.67 |
| 1994-12-31 | $6.78B | $4.32B | 1.57 |
| 1994-09-30 | $6.25B | $4.15B | 1.50 |
| 1994-06-30 | $6.32B | $3.75B | 1.69 |
| 1994-03-31 | $5.77B | $3.84B | 1.50 |
| 1993-12-31 | $5.47B | $3.87B | 1.41 |
| 1993-09-30 | $6.02B | $3.82B | 1.58 |
| 1993-06-30 | $5.78B | $4.21B | 1.37 |
| 1993-03-31 | $5.24B | $4.45B | 1.18 |
| 1992-12-31 | $4.87B | $4.72B | 1.03 |
| 1992-09-30 | $4.63B | $5.47B | 0.85 |
| 1992-06-30 | $4.49B | $5.03B | 0.89 |
| 1992-03-31 | $4.37B | $5.06B | 0.86 |
| 1991-12-31 | $4.57B | $5.03B | 0.91 |
| 1991-09-30 | $3.91B | $5.07B | 0.77 |
| 1991-06-30 | $3.97B | $4.83B | 0.82 |
| 1991-03-31 | $3.61B | $5.18B | 0.70 |
| 1990-12-31 | $3.96B | $5.09B | 0.78 |
| 1990-09-30 | $3.49B | $5.01B | 0.70 |
| 1990-06-30 | $3.39B | $4.68B | 0.73 |
| 1990-03-31 | $3.19B | $4.74B | 0.67 |
| 1989-12-31 | $3.79B | $4.54B | 0.84 |
| 1989-09-30 | $3.18B | $4.53B | 0.70 |
| 1989-06-30 | $3.32B | $4.31B | 0.77 |
| 1989-03-31 | $3.09B | $4.48B | 0.69 |
| 1988-12-31 | $0.36B | $4.30B | 0.08 |
| 1988-09-30 | $3.03B | $4.25B | 0.71 |
| 1988-06-30 | $3.06B | $4.13B | 0.74 |
| 1988-03-31 | $2.91B | $4.04B | 0.72 |
| 1987-12-31 | $3.02B | $3.88B | 0.78 |
| 1987-09-30 | $2.03B | $3.78B | 0.54 |
| 1987-06-30 | $2.05B | $3.64B | 0.56 |
| 1987-03-31 | $1.79B | $3.58B | 0.50 |
| 1986-12-31 | $1.79B | $3.42B | 0.52 |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Large Cap Pharmaceutical | $156.812B | $62.579B |
| Pfizer Inc. is a research-based, global biopharmaceutical company. The company boasts a sustainable pipeline with multiple late-stage programs that can drive growth. Pfizer markets a wide range of drugs and vaccines. Its business comprises six business units - Oncology, Inflammation & Immunology, Rare Disease, Hospital, Vaccines and Internal Medicine. Pfizer spinned-off its Upjohn unit, its off-patent branded and generic established medicines business, and combined it with generic drugmaker Mylan to create a new generic pharmaceutical company called Viatris. The Consumer Healthcare (CHC) segment, an over-the-counter (OTC) medicines business, was merged with Glaxo's unit to form a new joint venture.?The Consumer Healthcare joint venture with Glaxo and the merger of Upjohn unit with Mylan has made Pfizer a smaller company with a diversified portfolio of innovative drugs and vaccines. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Eli Lilly (LLY) | United States | $981.092B | 42.96 |
| Johnson & Johnson (JNJ) | United States | $586.690B | 22.54 |
| AbbVie (ABBV) | United States | $409.150B | 23.15 |
| Roche Holding AG (RHHBY) | Switzerland | $372.740B | 0.00 |
| Novartis AG (NVS) | Switzerland | $344.536B | 18.16 |
| Merck (MRK) | United States | $301.342B | 13.53 |
| Novo Nordisk (NVO) | Denmark | $221.330B | 12.68 |
| Sanofi (SNY) | France | $112.219B | 10.39 |
| Bayer (BAYRY) | Germany | $53.369B | 9.37 |
| Innoviva (INVA) | United States | $1.697B | 8.50 |